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Application of animal-free recombinant bioactive proteins 




1. Madin Darby Canine Kidney (MDCK)
2. VERO African Green Monkey Kidney (VERO)
3. Human Embryonic Kidney 293 (HEK 293)
Culture media:
Cells were maintained in Dulbecco's Modified Eagle's Medium / Ham's Nutrient 
Mixture F12 (DMEM /F12) supplemented with 2 mM GlutaMax™ and 10%(v/v) 
Foetal Bovine Serum.
Supplements:
Bioactive proteins tested and their final concentrations in media were:
LONG®R3 insulin-like growth factor-I (LR3): 100 µg/litre
LONG® Epidermal Growth Factor (LONG EGF): 20 µg/litre
CellPrime® rAlbumin AF-G (AF-G): 1 g/litre
CellPrime® rTransferrin AF (rTf): 5 mg/litre
LONG®R3 IGF-I is available from SAFC Biosciences, LONG EGF is available through Novozymes 
Biopharma, and CellPrime AF-G and rTransferrin are available through Millipore.
Batch culture:
Cells were harvested from tissue-culture flasks and washed twice with 
DMEM/F12 basal medium. Cells were counted then diluted in basal medium with 
2 mM GlutaMax™. 180 µL of cell suspension containing 4,000 cells was seeded 
into the wells of a 96-well culture plate (Corning®CellBIND® Surface, Cat. 3300). 
Supplements were added to a final volume of 200 µL. 
All conditions were tested in triplicate. The plates were incubated at 37 C, 5% 
CO2 for 6 days.
Cell growth: 
Cell growth was assessed by the CyQUANT NF Cell Proliferation Assay kit 
(Invitrogen). Results are expressed as Relative Fluorescence Units (RFU).
Introduction
The use of mammalian cell culture for the production of both pharmaceutical 
proteins and viral vaccines has grown dramatically over recent decades. The 
increased demand for cell-derived products has been accompanied by rapid 
developments in process technology and radical changes in the design of culture 
media. The progressive availability of relevant bioactive proteins using 
recombinant DNA technology has allowed the replacement of animal-derived 
components in the production process; this has assisted the efforts of regulatory 
bodies to minimise the potential risk to product users. The use of bioactive 
proteins has also contributed to greater consistency in process performance and 
provided the scope to elevate process yields. Examples of typically used bioactive 
proteins are listed in Table 1. 
Although individual proteins may have a significant effect on cell growth and 
productivity, the effect on performance can be enhanced further when particular 
proteins are used in combination. The industrial application of these proteins has 
largely focused on recombinant Chinese Hamster Ovary (CHO) cell lines producing 
pharmaceutical proteins. This poster presents the results of a preliminary study 
where the growth responses to a selection of bioactive proteins (Insulin-like 
growth factor, Epidermal growth factor, Transferrin and Albumin) were tested in 
three cell lines that are important in the production of viral vaccines.
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Results
Effect of bioactive proteins on vaccine cell line growth when used 
individually and in combination
Fig. 2. VERO cell growth
 VERO cells (Fig.2) showed an increased growth response when LR3 
was tested in combination with either LONG EGF or transferrin. The 
strongest response was observed when all three proteins (LR3, LONG 
EGF and transferrin) were added together to the medium (105% 
above control culture growth), qualitatively similar to the response 
seen with MDCK cells.
Fig. 3. HEK 293 cell growth
 HEK 293 cells (Fig.3) showed increased growth with the single addition of 
either albumin or transferrin (140% and 150% respectively above 
control). Growth was enhanced further when LR3 plus transferrin were 
tested in combination (170% above control) and when albumin plus 
transferrin were tested in combination (210% above control). The greatest 
improvement to growth was observed when LR3, transferrin and albumin 
































The combinations of bioactive proteins tested had a greater effect on cell growth of 
these cell lines than did the individual proteins.
The combination of LR3, LONG EGF and rTf showed strong growth enhancement 
across all three cell lines. 
Further work will examine the most effective concentrations and combinations of 
these bioactive proteins for growth of the individual cell lines.
Further work will also examine how these bioactive proteins influence the 
production of virus by these cell lines.
 MDCK cells (Fig.1) showed an increased growth response to media 
supplemented with transferrin. This response was enhanced by the 
addition of either LR3 (260% above control) or albumin (240% above 
control). The three components tested together increased the 
response further (560% above control), with a similar response 
observed when LONG EGF, LR3 and transferrin were tested in 
combination (450% above control).
